Skip to content

Subclinical Organ Damage in Overweight and Obese Patients: Does Presence of Metabolic Syndrome Matter?

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01586754
Enrollment
100
Registered
2012-04-27
Start date
2011-10-31
Completion date
2012-05-31
Last updated
2012-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Obese, Overweight, Subclinical Organ Damage

Keywords

metabolic syndrome, obesity, endothelial damage, homocysteine, microalbumin, carotis intima-media thickness

Brief summary

Microalbuminuria and homocysteine levels are shown to be markers for endothelial dysfunction and subclinical organ damage and predictors of cardiovascular risk in several epidemiologic and randomized clinical trials. Carotis intima-media thickness is also found to be elevated in early stages of atherosclerosis. Recent studies have shown correlations between homocysteine, microalbumin levels and carotis intima-media thickness in type 2 diabetics but no data exists for obese or overweight patients who also have metabolic syndrome, in terms of markers of subclinical organ damage. Since obesity is a risk factor for cardiovascular disease and since it is known that patients with metabolic syndrome are at higher risk of cardiovascular events, the investigators wanted to examine whether there is an association between homocysteine, microalbumin levels and carotid intima-media thickness in patients with or without metabolic syndrome, who are either overweight or obese.

Interventions

None listed

Sponsors

Goztepe Training and Research Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. 18-80 years 2. BMI \>= 25 3. Ex or non-smokers (must have quit smoking at least 5 years ago)

Exclusion criteria

1. NIDDM or IDDDM 2. Nephropathy (GFR \< 60 ml/min), previous history of coronary artery disease or peripheral arterial disease 3. Current smokers 4. Active infection or other acute illness

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026